Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AIM

AIM ImmunoTech Inc

Sep 13 • 04:00PM ET

0.2969

Dollar change -0.0031
Percentage change -1.03	%

Healthcare • Biotechnology • USA • AMEX

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.57	Insider Own	8.57%	Shs Outstand	57.14M	Perf Week	-9.48%
Market Cap	16.96M	Forward P/E	-	EPS next Y	-0.32	Insider Trans	7.36%	Shs Float	52.24M	Perf Month	8.44%
Income	-28.05M	PEG	-	EPS next Q	-0.08	Inst Own	14.78%	Short Float	1.00%	Perf Quarter	-27.78%
Sales	0.20M	P/S	84.82	EPS this Y	45.83%	Inst Trans	-3.18%	Short Ratio	2.18	Perf Half Y	-10.97%
Book/sh	0.11	P/B	2.78	EPS next Y	1.54%	ROA	-113.70%	Short Interest	0.52M	Perf Year	-52.11%
Cash/sh	0.18	P/C	1.69	EPS next 5Y	25.00%	ROE	-154.79%	52W Range	0.25 - 0.64	Perf YTD	-32.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	42.86%	ROI	-408.05%	52W High	-53.61%	Beta	-0.36
Dividend TTM	-	Quick Ratio	1.17	Sales past 5Y	-2.98%	Gross Margin	-43.28%	52W Low	18.24%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	1.17	EPS Y/Y TTM	-41.91%	Oper. Margin	-15708.96%	RSI (14)	36.46	Volatility	10.55% 10.11%
Employees	26	Debt/Eq	0.55	Sales Y/Y TTM	19.64%	Profit Margin	-13952.74%	Recom	1.00	Target Price	4.25
Option/Short	No / Yes	LT Debt/Eq	0.13	EPS Q/Q	65.68%	Payout	-	Rel Volume	0.71	Prev Close	0.30
Sales Surprise	42.86%	EPS Surprise	75.67%	Sales Q/Q	19.05%	Earnings	Aug 16 BMO	Avg Volume	238.91K	Price	0.30
SMA20	-12.81%	SMA50	-14.10%	SMA200	-27.39%	Trades		Volume	169,134	Change	-1.03%

Sep-11-24 09:00AM	AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential to Improve the Post-COVID Condition of Fatigue (GlobeNewswire)
Aug-20-24 08:30AM	AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research (GlobeNewswire) +15.32%
Aug-16-24 07:00AM	AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-13-24 09:05AM	AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast (GlobeNewswire)
Jul-29-24 09:15AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
08:50AM	Loading…
Jul-24-24 08:50AM	AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy (GlobeNewswire) -7.22%
Jul-03-24 08:55AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +6.49%
Jun-10-24 08:55AM	AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference (GlobeNewswire) -6.35%
Jun-03-24 09:15AM	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series (GlobeNewswire)
May-31-24 08:30AM	AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering (GlobeNewswire)
May-20-24 09:15AM	AIM ImmunoTech to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-16-24 07:30AM	AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 08:50AM	AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast (GlobeNewswire)
May-06-24 08:30AM	AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen (GlobeNewswire)
Apr-29-24 08:55AM	AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer (GlobeNewswire)
08:45AM	Loading…
Apr-25-24 08:45AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) -5.47%
Apr-18-24 08:45AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Apr-15-24 08:55AM	AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs (GlobeNewswire) -13.74%
Apr-11-24 11:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +10.05%
Apr-10-24 08:21AM	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer (GlobeNewswire) +12.96%
Apr-02-24 07:30AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.18%
Mar-28-24 08:05AM	AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire) +6.32%
Mar-26-24 09:05AM	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast (GlobeNewswire)
Mar-25-24 09:05AM	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research (GlobeNewswire)
Mar-22-24 08:55AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +16.46%
Mar-20-24 09:25AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Mar-15-24 08:45AM	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity (GlobeNewswire)
Mar-07-24 08:45AM	AIM ImmunoTech Announces Launch of CEO Corner Platform (GlobeNewswire)
Feb-29-24 08:45AM	AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update (GlobeNewswire)
Feb-14-24 08:55AM	AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
08:50AM	Loading…
Feb-08-24 08:50AM	AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire) -12.64%
Jan-24-24 09:10AM	AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire) -6.88%
Jan-22-24 08:55AM	AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZenecas Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer (GlobeNewswire)
Jan-10-24 08:45AM	AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jan-05-24 01:32PM	AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting (Business Wire) -8.14%
Jan-03-24 04:05PM	Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied (PR Newswire)
Dec-29-23 08:00AM	Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Boards Determination that Activist Groups Nominations Are Invalid (Business Wire) -8.73%
Nov-28-23 04:30PM	AIM ImmunoTech Provides Update Regarding Annual Meeting (Business Wire) +7.27%
Nov-27-23 09:00PM	AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents (GlobeNewswire)
Nov-21-23 12:00PM	AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Nov-16-23 08:45AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change (PR Newswire)
Nov-15-23 07:30AM	AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update (GlobeNewswire)
Nov-14-23 10:00AM	AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer (GlobeNewswire)
Nov-09-23 08:05AM	AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast (GlobeNewswire) -8.12%
Nov-08-23 08:45AM	AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer (GlobeNewswire)
Nov-06-23 09:25AM	AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders (Business Wire) -8.99%
Oct-30-23 08:55AM	AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) +6.98%
Oct-17-23 08:45AM	AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs (GlobeNewswire) +10.43%
Sep-22-23 09:05AM	AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (GlobeNewswire)
Sep-11-23 01:00PM	AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer (GlobeNewswire) +7.97%
Sep-05-23 09:05AM	AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-23-23 08:00AM	AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements (Business Wire)
Aug-15-23 06:45AM	AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update (GlobeNewswire) -6.34%
Aug-09-23 09:05AM	AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast (GlobeNewswire)
Aug-08-23 08:05AM	AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Jul-18-23 07:30PM	AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates (GlobeNewswire) +8.43%
06:53AM	Daily Vickers Top Buyers & Sellers for 07/18/2023 (Argus Research)
Jul-10-23 08:05AM	AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Jul-05-23 08:35AM	AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series (GlobeNewswire)
Jun-27-23 11:16AM	AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research (GlobeNewswire) +7.02%
08:45AM	AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jun-14-23 08:45AM	AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire)
Jun-12-23 08:45AM	AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments (GlobeNewswire)
Jun-07-23 07:11PM	AIMIA ADOPTS SHAREHOLDER RIGHTS PLAN TO PROTECT AGAINST "CREEPING" BIDS AND UNEQUAL TREATMENT OF SHAREHOLDERS (PR Newswire)
May-15-23 08:45AM	AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update (GlobeNewswire)
May-09-23 08:50AM	AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast (GlobeNewswire)
08:46AM	AIMIA ANNOUNCES CLOSING OF BOZZETTO TRANSACTION (PR Newswire)
Apr-20-23 03:56PM	AIMIA'S LARGEST SHAREHOLDER THANKS FELLOW SHAREHOLDERS FOR SUPPORTING CHANGE; MITHAQ EXPLORING ALL OPTIONS TO ENSURE VALIDITY OF RESULTS (PR Newswire)
Apr-12-23 08:35AM	AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB) (GlobeNewswire) +9.15%
07:30AM	AIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINE (PR Newswire)
Apr-10-23 07:30AM	AIMIA'S LARGEST SHAREHOLDER ENCOURAGES FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD (PR Newswire)
Apr-04-23 08:45AM	AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire) +6.05%
Apr-03-23 06:30AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-30-23 08:45AM	AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise (GlobeNewswire)
Mar-27-23 09:05AM	AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast (GlobeNewswire) -5.05%
Mar-16-23 08:45AM	AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease (GlobeNewswire) +5.00%
07:00AM	AIMIA REPORTS FOURTH QUARTER 2022 RESULTS (PR Newswire)
07:00AM	AIMIA DECLARES PREFERRED SHARE DIVIDENDS (PR Newswire)
Mar-08-23 08:45AM	AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease (GlobeNewswire)
Mar-06-23 08:45AM	AIM ImmunoTech Issues Letter to Stockholders (GlobeNewswire)
Feb-28-23 08:45AM	AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients (GlobeNewswire) +8.37%
Feb-17-23 08:55AM	AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, Long Covid: What Will It Take To Accelerate Therapeutic Progress? (GlobeNewswire) +6.40%
Jan-17-23 08:45AM	AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center (GlobeNewswire) +22.53%
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE) +21.75%
Jan-09-23 08:05AM	AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention (GlobeNewswire)
Jan-05-23 08:45AM	AIM ImmunoTech to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire) +13.54%
Dec-12-22 09:00AM	AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer (GlobeNewswire)
Dec-08-22 08:05AM	AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects (GlobeNewswire)
Dec-02-22 10:45AM	AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022 (GlobeNewswire)
Nov-15-22 07:00AM	AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-14-22 07:00AM	AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer (GlobeNewswire) -6.82%
Nov-09-22 09:00AM	AIM ImmunoTech Announces Corporate Governance Enhancements (Business Wire)
Nov-03-22 12:34PM	AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting (Business Wire)
Nov-02-22 07:05AM	AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease (GlobeNewswire)
Nov-01-22 05:19PM	Statement of the ASFV Committee on Ruling in Delaware Action (GlobeNewswire)
Oct-31-22 07:30AM	Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Groups Nominations Valid (Business Wire) +5.05%
Oct-26-22 05:12PM	AIM ImmunoTech Board Issues Letter to Shareholders (Business Wire)
Oct-24-22 08:30AM	ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action (GlobeNewswire)
Oct-13-22 10:32AM	U.S. District Court Dismisses AIMs "Baseless" Section 13(d) Claim (GlobeNewswire)
Oct-12-22 04:32PM	AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions (GlobeNewswire) -7.87%

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Equels Thomas K	CEO & President	May 06 '24	Buy	0.41	61,729	25,000	778,184	May 07 08:30 AM
Rodino Peter W III	COO, Secretary, Gen. Counsel	May 06 '24	Buy	0.41	30,865	12,500	212,583	May 07 08:30 AM
BRYAN NANCY	Director	Mar 21 '24	Buy	0.39	38,462	15,000	38,462	Mar 22 01:30 PM
APPELROUTH STEWART	Director	Mar 15 '24	Buy	0.33	90,910	30,000	239,765	Mar 18 03:01 PM
Equels Thomas K	CEO & President	Mar 15 '24	Buy	0.33	75,758	25,000	716,455	Mar 18 03:01 PM
Rodino Peter W III	COO, Secretary, Gen. Counsel	Mar 15 '24	Buy	0.33	37,879	12,500	181,718	Mar 18 03:01 PM
Equels Thomas K	CEO & President	Nov 27 '23	Buy	0.44	33,861	15,000	640,697	Nov 27 12:56 PM
Equels Thomas K	CEO & President	Sep 29 '23	Buy	0.44	22,676	10,000	606,836	Sep 29 03:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIM

AIM ImmunoTech Inc

Upgrade your FINVIZ experience